1 **Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and**
2 **induce intestinal barrier defects *ex vivo* in murine intestinal tissue**
3

4 Frida Fart[1], Samira Salihovic[1,2], Aidan McGlinchey[1], Melanie G. Gareau[3], Matej Orešič[1,4],
5 Jonas Halfvarson[5§,], Tuulia Hyötyläinen[2§], Ida Schoultz[1§#]
6

[1]School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden, [2]School of Science
and Technology, Örebro University, 702 82, Örebro, Sweden, [3]Department of Anatomy,
Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis,
Davis, CA, US [4]Turku Bioscience Centre, University of Turku and Åbo Akademi University,
20520 Turku, Finland, [5]Department of Gastroenterology, Faculty of Medicine and Health,
Örebro University, 702 81 Örebro, Sweden. §Shared senior authorship

Abstract
15

Background and aim: Environmental factors are strongly implicated in late-onset
inflammatory bowel disease. By measuring perfluoroalkyl substances we investigate whether
high exposure correlates with late-onset inflammatory bowel disease, and disturbances of the
bile acid pool. We further explore the effect of perfluoronoctanoic acid on intestinal barrier
function in murine tissue.
Methods: Serum levels of perfluoroalkyl substances and bile acids were assessed in matched
samples from patients with ulcerative colitis (n=20) and Crohn's disease (n=20) diagnosed at
the age of ≥55 years. Blood donors (n=20), were used as healthy controls. The metabolites
were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole
mass spectrometer. *Ex vivo* exposure of perfluoronoctanoic acid in ileal and colonic murine
tissue was assessed with the Ussing Chamber methodology (n=5).
Results: The total level of perfluoroalkyl substances was significantly increased in patients
with ulcerative colitis compared to healthy controls or patients with Crohn's disease ($p<0.05$).
Ex vivo exposure of 100 µM perfluoronoctanoic acid induced a significantly increased
paracellular permeability across ileum ($p<0.05$) and an enhanced carbachol-induced ion
secretion in colon. The distribution of bile acids as well as the correlation pattern between
perfluoroalkyl substances and bile acids differed between patient groups and controls.
Conclusion: Our results demonstrate that the levels of perfluoroalkyl substances are
increased in patients with late-onset ulcerative colitis and might contribute to the disease by
inducing a dysfunctional intestinal barrier or indirectly by interfering with the bile acid
metabolism and thereby alter the intestinal barrier function.

Address for correspondence:
Ida Schoultz, PhD, School of Medical Sciences, Örebro University, Södra Grev Rosengatan
30, 703 30 Örebro university, Sweden. Phone/fax: +46 19 30 32 09, email:
ida.schoultz@oru.se

Introduction

Inflammatory bowel disease (IBD), including the two main subtypes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disease of the gastrointestinal tract. IBD is most often diagnosed in late adolescence or young adulthood (15-35 years of age), but recent evidence indicates that the incidence of late-onset IBD, often defined as diagnosed at >50 years of age, is increasing.[1] The disease is thought to develop as a result of complex interactions between environmental factors, genetic susceptibility, barrier dysfunction and altered gut microbiota. Current knowledge suggest that late-onset IBD is more linked to environmental risk factors and is associated with a lower genetic risk score compared to earlier onset.[2] Even though several environmental risk factors, including dietary factors have been associated with IBD, their underlying pathophysiological mechanisms are largely unknown.[3]

The intestinal mucosal barrier maintains homeostasis and prevent the entry of harmful components while simultaneously absorb essential nutrients.[4] Disruption of the mucosal barrier, resulting in an increased intestinal permeability, with augmented passage of non-pathogenic bacteria, is believed to play a key role in the pathophysiology of IBD.[4,5] Some environmental risk factors, such as emulsifiers and oral exposure to heavy metals, may in fact mediate their effect through modulation of the mucosal barrier.[6,7] One of the main chemical groups that humans are exposed to through food is perfluoroalkyl substances (PFAS) which are man-made chemicals with a long biological half-life in humans, and PFAS have been extensively used since the 1950s, in non-stick cookware and flame retardands, amongst other uses. Even though the use of some PFAS such as perfluorooctane sulfonate (PFOS) and perfluoronoctanoic acid (PFOA) have been either prohibited or restricted, exposure to these substances still occurs as they are still found in the environment. Moreover, several of the current substitutes within the PFAS substance class, such as fluorotelomer alcohols, are

precursors of several toxic PFAS, including PFOA.[8–10] An increased incidence of UC has

previously been reported in response to a high exposure of PFOA through contaminated

drinking water in mid-Ohio.[11] Findings from animal studies show that PFOA alter the

adaptive and innate immune response and may influence gut barrier function through

induction of various regulatory cytokines.[12] However, if exposure to PFOA translate into

alterations in the immune response and gut barrier function also in humans is largely

unknown. It has recently been shown that PFAS utilize the same enterohepatic circulation as

bile acids (BAs) and that PFAS may impact the absorption of BAs in the small intestine.[13,14]

The BAs are synthesized from cholesterol in the liver and these primary BAs are then

conjugated either with glycine or taurine, and transported through the biliary system into the

small intestine where they can be modified to secondary BAs by the gut microbiota. Beyond

facilitating the digestion and absorption of lipids in the small intestine, BAs possess

antibacterial properties, of relevance for the gut mucosal defense, including intestinal

permeability.[13] Dysregulation of intestinal BAs has further been implicated in the

pathogenesis of IBD[15,16] and *ex vivo* exposure of BAs have been shown to induce an increase

in intestinal permeability and bacterial uptake across the colonic mucosa.[17]

We therefore hypothesized that chronic exposure to PFAS contributes to the development of

late-onset IBD, by inducing an altered intestinal barrier function or indirectly by interfering

with the BAs metabolism and, thereby alter the intestinal barrier function. Here we investigate

the level of PFAS and their relation to primary and secondary BAs in patients who develop

IBD later in life. Moreover, we explore the effect of PFOA, one of the major PFAS, on the

intestinal barrier function by performing *ex vivo* experiments of ileal and colonic murine

tissue using the Ussing Chamber.

2. Material and Methods

2.1 Study design

This is a case-control study where serum concentrations of PFAS and BAs were assessed in patients with late-onset IBD, defined as UC and CD diagnosed ≥55 years (cases), and age- and sex-matched blood donors without any history of chronic gastrointestinal disease, i.e. healthy controls (HC). Comparisons with late-onset CD patients were also stratified for disease location, since BAs are reabsorbed in the terminal ileum. Based on the observed association between exposure of PFOA and late-onset disease, we investigated the effect of PFOA on ileal and colonic barrier function in wild type mice using an Ussing Chamber.

2.2 Study population

The samples from IBD patients used in this study were obtained from a previously described cohort.[18] Briefly, patients with CD or UC were consecutively recruited at the outpatient IBD clinic of Örebro University Hospital, Sweden. Blood samples were collected after receiving informed written consent and serum was separated according to standard operating procedures,[19] aliquots were stored at -80°C until further analysis. The diagnosis of IBD was based on internationally accepted clinical, endoscopic, radiologic and histologic criteria.[20] The Montreal classification was used for assessment of disease characteristics.[21] A sample set of 20 late-onset UC and 20 late-onset CD patients, whom are diagnosed at/after age 55, matched by age (± 5 years), sex and disease duration (± 5 years) were selected. HC are matched by age (± 5 years) and sex were included as controls (median age 59 years, IQR 56-61 years). Clinical characteristics and demographics of IBD patients included in the study are shown in Table 1. None of the patients were included at disease onset and blood samples were obtaine, by median, 7 to 8 years after diagnosis.

2.3 Analysis of BAs and PFAS

The levels of PFAS and BAs were assessed by ultra-performance liquid chromatography

coupled to a triple quadrupole mass spectrometer as previously described.[22] Briefly, all

samples were prepared and analysed simultaneously in a randomised order in one batch to

minimize potential bias. A positive and negative control as well as certified reference material

were included in the analyses to assess accuracy and consistency.

2.4 Ex vivo Ussing Chamber experiments

The Ussing chamber experiments were performed as described previously.[23] Briefly,

segments of distal ileum and proximal colon from adult (6-8 week) wild type mice (C57BL/6,

Jackson Labs, bred in house at UC Davis) were excised. The segments were cut along the

mesenteric border and mounted in Ussing chambers (Physiologic Instruments, San Diego,

CA), exposing 0.1 cm^2 of tissue area with circulating oxygenated Ringer's buffer (4 ml)

maintained at 37°C. Additionally, glucose (10 mM) was added to the serosal buffer as a

source of energy, which was balanced osmotically by mannitol (10 mM) in the mucosal

buffer. Agar-salt bridges were used to monitor potential differences across the tissue and to

inject the required short-circuit current (Isc) to maintain the potential difference at zero as

registered by an automated voltage clamp. A computer connected to the voltage clamp system

recorded Isc and voltage continuously and the data was analysed using acquisition software

(Acquire and Analyze; Physiologic Instruments). Baseline Isc values ($\mu A/cm^2$), indicative of

active ion transport, were obtained at equilibrium, approximately 15 min after the tissues were

mounted. PFOA (Sigma) was added to both the serosal and mucosal side of the chamber in

the concentrations of: 100 μM and 10 μM at baseline. Conductance (G; mS/cm^2) was used to

assess tight junction permeability and mucosal to serosal flux of 4KDa FITC-labeled dextran

(Sigma) over time (sampled every 30 minutes for 2 hours) was used to assess macromolecular

permeability. After completion of the FITC flux measurements, tissues were treated with

carbachol (CCh, 10^{-5} μM; Sigma) to assess the stimulated secretory response to PFOA.

2.5 Statistical considerations

For statistical analyses of PFAS and BA concentrations, the data was zero imputed, log2

transformed and autoscaled. The statistical analyses were performed using IBM SPSS

statistics, MetaboAnalyst436[24] and MetScape 3 for CytoScape.[25] In SPSS, a general linear

model was fitted to investigate the associations between PFAS and BAs across the groups,

after controlling for confounding factors (age and the year of sampling). To show the

direction of the change between groups, the data is presented as fold change (i.e ratio)

between CD, UC and HC. Correlation analyses were done using the Spearmann correlation

analyses. The Debiased Sparse Partial Correlation algorithm was used for estimating partial

correlation networks, visualised by the MetScape4 version with cut-off values of correlations

between ± 0.22 to 0.75. When stratifying for ileal and colonic disease location in CD patients,

Mann-Whitney U analysis was performed.

For analysis of Ussing Chamber experiments Kruskal-Wallis and the Mann-Whitney U-

analysis (GraphPad Prism 8) was used to assess intestinal permeability, FITC-dextran passage

and stimulated secretory response. Values of $p<0.05$ were considered statistically significant.

The degree of significance for Ussing Chamber experiments was indicated as follows: $p<0.05$

[*], $p<0.01$ [**], non-significant [ns].

2.5 Ethical statement

The Local Ethics Committee approved the study (Dnr: 2006/245), and all patients as well as

external controls gave their written informed consent. All animal procedures and protocols

were approved by UC Davis animal care and use committee (IACUC #20072).

3. Results

3.1 Serum concentrations of PFAS in late-onset UC and CD

The concentrations of PFAS was assessed in serum samples and are shown in table S1. The

total level of PFAS ($\sum$PFAS, p=0.03), PFOS (p=0.03) and PFOA (p=0.02) was found to be

significantly increased in UC compared to HC (Table 2). In contrast the PFAS levels were not

signficanlty different in CD and HC. Similarly, UC had significantly higher levels of $\sum$PFAS

(p=0.03), PFOS (p=0.03) perfluorononanoic acid (PFNA, p=0.03), perfluorodecanoic acid

(PFDA, p=0.005) and perfluoroundecanoic acid (PFUnDA, p=0.03) compared to CD. A

correlation network analysis further showed that disease is the major factor influencing the

serum level of PFOA and that the PFAS were closely linked with the BAs (Figure 1).

3.2 Ussing Chamber experiments

Intestinal permeability was assessed by measuring G for tight junction permeability and flux

of FITC-dextran as an indicator of macromolecular permeability. *Ex vivo* exposure to

intestinal murine tissue to PFOA at 100 µM resulted in a significant increase in ileal

permeability at 60 minutes compared to baseline, while no significant changes were observed

in colonic tissue (Figure 2a-b). An increased flux of FITC-dextran was observed in ileal tissue

after exposure to 10 µM PFOA compared to colonic tissue, however, this observation was not

statistically significant (Figure 2c-d). Stimulated ion transport across the ileal tissue, assessed

by ΔIsc, was not impaired after exposure to PFOA, however an increased response to CCh

after exposure to 100 µM PFOA was observed across colonic epithelium compared to vehicle

(DMSO) (Figure 2e-f).

3.3 Serum BAs concentrations in UC and CD patients

The concentrations of BA was assessed in serum samples and are shown in table S1.

The level of primary BAs (free and conjugated BAs) were found to be decreased in UC as compared to HC (p=0.02), Table 3, while no differences could be observed in secondary BAs or the total level of taurine-conjugated BAs (ΣTBA) and glycine-conjugated BAs (ΣGBA). Primary BAs were decreased in CD as compared to HC (p=0.02), except for the free chenodeoxycholic acid (CDCA) which was increased in CD (p=0.006). Moreover, the ratio of the two primary BAs, cholic acid (CA) and CDCA (CA/CDCA) was significantly decreased in CD vs HC and UC (p=0.02), while no difference was seen regarding the ratio between UC and HC.The total level of TBA (ΣTBA) was significantly decreased in CD vs HC (p=0.003), while no differences was found in the total level of GBA. The secondary conjugated BAs were found to be significantly increased in CD patients as compared to HC (p=0.007). In addition, primary BAs were significantly decreased in CD vs UC (p=0.0001), while CDCA was present in an increased level in CD (p=0.001). The distribution of the BAs in the different groups are illustrated in Figure 4.

Comparisons of BAs levels were further stratified for disease location in CD according to the Montreal classification, Table 4. Ileal involvement (L1 and L3) was associated with a prominent decrease of $\sum$TBA (p=0.01) and the glycine-conjugated BA glycohyocholic acid (GHCA, p=0.02) as well as an increase of both of the free primary BAs (CDCA, p=0.008 and CA, p=0.04) and the secondary BAs hyodeoxycholic acid (HDCA, p=0.004) and ursodeoxycholic acid (UDCA, p=0.004), Table 4. The low number of non-resected patients with ileal involvement (n=3) did not allow us to examine the influence of previous resection among CD patients.

3.4 Correlations of PFAS and BAs

The total level of PFAS, ($\sum$PFAS) was found to correlate positively with taurohyocholic acid,

taurochenodeoxycholic acid (TCDCA) and $\sum$TBA among patients with late-onset UC, as

visualized by a correlation heat map given in Figure 3. In addition, PFOS correlated positively

with taurolitocholic acid (TLCA), while PFUnDA correlated positively with taurine-

conjugates of α- and β- muricholic acid (Tα+βMCA) among these patients. On the contrary,

PFDA showed a negative correlation with CA and TLCA. In CD, the total level of PFAS

showed a positive correlation with taurochenodeoxycholic acid (TCDCA), GHCA and $\sum$TBA.

PFNA and PFDA also correlated positively with Tα+βMCA. In control subjects the

correlation pattern was different compared to UC and CD, where $\sum$PFAS showed a negative

correlation to UDCA and positive correlation to TLCA

4. Discussion

In the present study we investigated the impact of PFAS on the risk of late-onset IBD, in relation to intestinal barrier function and BA metabolism. Our findings demonstrate that serum PFAS levels, particularly PFOS and PFOA, are increased among late-onset UC patients. Interestingly, BA levels differed depending on disease status, and between the associations of PFAS and BA concentrations. The role of PFAS in IBD was further supported by our *ex vivo* study of mice tissue, where exposure to PFOA resulted in increased ileal permeability and the enhanced colonic secretory response to CCh. These findings suggest that PFAS has the potential to alter the intestinal barrier function.

PFAS has been associated with various adverse health effects, including cancer, liver damage, decreased fertility, and increased risk of chronic inflammatory diseases. Contamination of drinking water with high levels of PFOA, one of the main PFAS, has also been associated with an increased incidence of UC in Ohio, US.[11] This observation indicates that PFAS also may play a role in IBD. In the current study, we observed higher PFAS levels among patients with late-onset UC in comparison to HC and CD. Particularly, PFOS and PFOA were increased among patients with UC. This finding is supported by a previous report on increased levels of PFOA among patients with UC, even though there was a pronounced difference in ethnicity between cases and controls.[26]

Disruption of the intestinal barrier is believed to represent a key disease-mechanism in IBD.[4] Given the observed increased levels of PFOA in UC, we investigated the impact of *ex vivo* exposure of PFOA on ileal and colonic barrier function in mice.[11,26] After exposure to PFOA (100μM), an increased ion transport, as assessed by Isc, was seen across the colonic epithelium in response to stimulation with CCh. Interestingly, we did not observe an increase

in colonic permeability after exposure to PFOA. This indicates that exposure to PFOA decreases the resilience of the colonic barrier and makes it more susceptible to stressors, rather than affecting it directly. The effect of PFOA may potentially be mediated by initiation of an increased Ca^{2+}- induced Cl^- secretion, since increased levels of Cl^- have previously been demonstrated in faecal material of UC patients.[27,28] An impaired sodium absorption/chloride secretion coupled with increased water secretion into the lumen has also been reported as a primary mechanism in IBD-associated diarrhoea.[29] Interestingly, an increased ileal tight junction permeability was also observed after exposure to PFOA, even though we did not observe an increased macromolecular passage of FITC-dextran across colonic or ileal tissue. This is in contrast to the previously reported negative correlation between exposure to PFAS and intestinal permeability among 170 patients/individuals.[30] In the current study, we used the Ussing chamber technology to assess barrier function, while the previous report relied on zonulin levels, for which the validity is currently questioned.[31,32] The increased variability seen in the FITC flux values may have contributed to the absence of statistical significance. More indepth future studies to characterise permeability *in vivo* would be highly insightful.

PFOA may induce an increased permeability by affecting pathways important for gut barrier integrity. The hepatocyte nuclear factor 4α (HNF4α), know be involved in the formation of tight junctions in the intestinal epithelium, has been shown to be inhibited by PFOA.[33] Interestingly, HNF4α mRNA expression is significantly decreased in IBD patients[34] and plays a central role in the regulation of BA metabolism in the liver, where it is both involved in the synthesis and conjugation of primary BAs. [35] Indeed, another potential mechanism via which PFAS might contribute to a dysfunctional intestinal barrier and the pathophysiology of IBD is by affecting the composition of the BA pool.[13,36,37] *In vitro* studies have previously shown that direct exposure of PFAS to a hepatocyte cell line induces strong alterations in the intra- and extracellular BA content with a dose-dependent decrease of intracellular BAs in response to

PFAS. In the present paper, we identify significant differences in the circulating levels of BAs in UC and CD in comparison with HC. An altered profile of circulating BAs in IBD has been reported previously.[15,38,39] Our results demonstrate that the total level of primary BAs is significantly decreased in UC and CD compared to HC. However, only patients with CD showed increased levels of the free primary CA and CDCA. Previous reports indicate that CDCA even in low physiological levels (100 µM), have the potential to induce an increased mucosal permeability and bacterial uptake in human colonic tissue.[17,40]

Moreover, the decrease in the ratio of CA/CDCA in CD, proposes that the synthesis of BAs are occurring via the alternative BA synthesis (normally accounting for only 10% of BAs) and not via the classical pathway in the liver. Hence, potentially indicating that CD is associated with a deficiency in the synthesis of BAs via the classical pathway.

The link between PFAS exposure and the composition of the BA pool is supported by the observed correlations between PFAS levels and the altered BA profile. In accordance with previous literature showing that PFAS supress the biosynthesis of BAs, we observed negative correlations between the total exposure of PFAS and total levels of primary and secondary BAs[13,36] among HC, only the secondary BA litocholic acid and its conjugates (GLCA, TLCA) showed a positive correlation. In addition IBD patients showed a different profile with positive correlations between total ∑PFAS and ΣTBA. This indicates a possible alteration of the deconjugation in the gut or alternatively an increased absorption of taurine conjugates from the intestine.

However, the changes observed in BA content in regard to CD, should be interpreted with caution, as most patients had ileal or ileocolonic CD. Both inflammation and resection of the terminal ileum are known to reduce the reabsorbtion of BA and in accordance with previous

studies,[39,41] ileal CD was associated with a increase of primary BA (CA and CDCA) and increase of secondary BAs (HDCA and UDCA), and an decrease in ΣTBA. The extent to which these alterations were explained by ongoing inflammation, previous resections, pronounced alterations in the composition and volatility of the gut microbiome or a combination of these could not be examined due to the small sample size.[42,43]

The current study has some limitations. First of all, the number of individuals in the study was low and results may have been influenced by previous or ongoing treatments, even though only one CD patients was prescribed BA sequestrants. Secondly, the HC group was slightly younger (mean age: 59) than the patients with IBD and their serum samples were obtained a few years later. However, possible confounding effects of age and year of sampling were accounted for in our statistical analysis and should not have any major impact on the results. Nevertheless, future studies should validate these results in a larger cohort, where samples from cases and controls are obtained within an identical period. Moreover, we were not able to relate our findings to the composition of gut microbiota, since stool samples were not available. Future studies should investigate this as recent evidence indicate that PFAS can directly affect the gut microbiota composition. In the present study, we selectively included patients with late-onset IBD, based on the hypothesis that exposure to environmental risk factors is more important among these patients. The extent to which our findings can be generalised to patients with younger onset IBD is unknown. There is also a need to validate the observed effects on the intestinal barrier in response to exposure of PFOA in functional studies of mucosal samples from patients with IBD.

In conclusion our study demonstrates that total levels of PFAS are significantly increased in patients with late-onset UC compared to HC and patients with CD and correlate to disturbances in the BA pool. Moreover, we propose that a possible mechanism via which

PFAS contribute to the pathophysiology of UC is by inducing a disruption of the intestinal barrier or indirectly by interfering with the BAs metabolism that subsequently contribute to an altered intestinal barrier function.

Funding

This work was supported by funding from the Faculty of Medicine and Health, Örebro University [grant number: ORU2018/04457 to I.S], Bo Rydin foundation [grant number: F0514 to I.S], Örebro Hospital Research Foundation [Grant number OLL-790011 to J.H] Swedish research council [grant number 2016-05176 to T.H], Formas [grant number. 2019-00869 to T.H and M.O].

Conflict of interest

JH: consulting fees from Abbvie, Celgene, Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, RenapharmaVifor, Sandoz, Shire Takeda, and Tillotts Pharma, and lecture fees from Abbvie, Ferring, Janssen, MSD, RenapharmaVifor, Shire, Takeda and Tillotts Pharma. Research grants from Janssen, MSD and Takeda. IS: lecture fees from Meda and Nutricia.
All other authors reported no conflicts of interest.

Acknowledgement

The authors wish to thank Dr Ciara Keogh and laboratory technician Jessica Sladek for skillful technical assistance in the Ussing laboratory, Davis, USA.

Author contributions

FF: Extracted clinical data, participated in the statistical analyses, interpretation of data and drafting of manuscript. SS: Performed laboratory analyses and participated

in interpretation of data. AM: Participated in the statistical analyses and interpretation of data. MG: Designed and performed parts of the Ussing Chamber experiments, participated in the drafting of manuscript, funding. MO: Study design, analysis and interpretation of data. JH: Responsible for patient inclusion and establishment of cohorts, participated in study concept and design, interpretation of data, drafting of manuscript, and funding. TH: Study concept and design, responsible for the statistical analysis, interpretation of data, drafting of manuscript, and funding. IS: Study concept and design, designed and performed parts of the Ussing Chamber experiments, analyses and interpretation of data, drafting of manuscript, funding.

5. References

1.   Everhov ÅH., Halfvarson J., Myrelid P., Sachs MC., Nordenvall C., Söderling J., et al. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. *Gastroenterology* 2018;**154**(3):518–28.

2.   Lee D., Albenberg L., Compher C., Baldassano R., Piccoli D., Lewis JD., et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology* 2015;**148**(6):1087–106.

3.   Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nature Reviews Gastroenterology & Hepatology* 2015;**12**(4):205–17. Doi: 10.1038/nrgastro.2015.34.

4.   Salim SY., Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. *Inflamm Bowel Dis* 2011;**17**(1):362–81.

5.   Nazli A., Yang P-C., Jury J., Howe K., Watson JL., Söderholm JD., et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. *Am J Pathol* 2004;**164**(3):947–57.

6.   Roberts CL., Keita AV., Duncan SH., O'Kennedy N., Söderholm JD., Rhodes

JM., et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. *Gut* 2010;**59**(10):1331–9.

7.   Nair N., Austin C., Curtin P., Gouveia C., Arora M., Torres J. Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. *Gastroenterology* 2020;**20**(0):30391–7.

8.   Ellis DA., Martin JW., De Silva AO., Mabury SA., Hurley MD., Sulbaek Andersen MP., et al. Degradation of fluorotelomer alcohols: a likely atmospheric source of perfluorinated carboxylic acids. *Environ Sci Technol* 2004;**38**(12):3316–21.

9.   Fasano WJ., Carpenter SC., Gannon SA., Snow TA., Stadler JC., Kennedy GL., et al. Absorption, distribution, metabolism, and elimination of 8-2 fluorotelomer alcohol in the rat. *Toxicol Sci* 2006;**91**(2):341–55.

10.   Huang MC., Robinson VG., Waidyanatha S., Dzierlenga AL., DeVito MJ., Eifrid MA., et al. Toxicokinetics of 8:2 fluorotelomer alcohol (8:2-FTOH) in male and female Hsd:Sprague Dawley SD rats after intravenous and gavage administration. *Toxicol Rep* 2019;**6**:924–32.

11.   Steenland K., Zhao L., Winquist A., Parks C. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. *Environ Health Perspect* 2013;**121**(8):900–5.

12.   DeWitt JC., Peden-Adams MM., Keller JM., Germolec DR. Immunotoxicity of perfluorinated compounds: recent developments. *Toxicol Pathol* 2012;**40**(2):300–11.

13.   Zhao W., Zitzow JD., Ehresman DJ., Chang S-C., Butenhoff JL., Forster J., et al. Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. *Toxicol Sci* 2015;**146**(2):363–73.

14.   Chiang JY. Recent advances in understanding bile acid homeostasis. *F1000Res*

2017;**6**:1–8.

15.   Duboc H., Rajca S., Rainteau D., Benarous D., Maubert M-A., Quervain E., et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. *Gut* 2013;**62**(4):531–9.

16.   Lavelle A., Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2020;**17**(4):223–37.

17.   Münch A., Ström M., Söderholm JD. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. *Scand J Gastroenterol* 2007;**42**(10):1167–74.

18.   Fransén K., Franzén P., Magnuson A., Elmabsout AA., Nyhlin N., Wickbom A., et al. Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of Crohn's Disease. *PLoS ONE* 2013;**8**(8):1–6.

19.   Drobin K., Assadi G., Hong M-G., Andersson E., Fredolini C., Forsström B., et al. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. *Inflamm Bowel Dis* 2019;**25**(2):306–16.

20.   Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989;**170**:2–6; discussion 16-19.

21.   Silverberg MS., Satsangi J., Ahmad T., Arnott IDR., Bernstein CN., Brant SR., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005;**19 Suppl A**:5A-36A.

22.   Salihović S., Dickens AM., Schoultz I., Fart F., Sinisalu L., Lindeman T., et al. Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* 2019;**412**:2251-9.

23.   Pusceddu MM., Barboza M., Keogh CE., Schneider M., Stokes P., Sladek JA., et al. Nod-like receptors are critical for gut-brain axis signalling in mice. *J Physiol (Lond)* 2019;**597**(24):5777–97.

24.   Chong J., Wishart DS., Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. *Curr Protoc Bioinformatics* 2019;**68**(1):1–128.

25.   Basu S., Duren W., Evans CR., Burant CF., Michailidis G., Karnovsky A. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. *Bioinformatics* 2017;**33**(10):1545–53.

26.   Steenland K., Kugathasan S., Barr DB. PFOA and ulcerative colitis. *Environ Res* 2018;**165**:317–21.

27.   Roediger WE., Lawson MJ., Kwok V., Grant AK., Pannall PR. Colonic bicarbonate output as a test of disease activity in ulcerative colitis. *J Clin Pathol* 1984;**37**(6):704–7.

28.   Schilli R., Breuer RI., Klein F., Dunn K., Gnaedinger A., Bernstein J., et al. Comparison of the composition of faecal fluid in Crohn's disease and ulcerative colitis. *Gut* 1982;**23**(4):326–32.

29.   Anbazhagan AN., Priyamvada S., Alrefai WA., Dudeja PK. Pathophysiology of IBD associated diarrhea. *Tissue Barriers* 2018;**6**(2):1–21.

30.   Xu Y., Li Y., Scott K., Lindh CH., Jakobsson K., Fletcher T., et al. Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water. *Environ Res* 2020;**181**:1–8.

31.   Ajamian M., Steer D., Rosella G., Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. *PLoS ONE* 2019;**14**(1):1–10.

32.   Scheffler L., Crane A., Heyne H., Tönjes A., Schleinitz D., Ihling CH., et al.

Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. *Front Endocrinol (Lausanne)* 2018;**9**:1–14.

33.   Scharmach E., Buhrke T., Lichtenstein D., Lampen A. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). *Toxicol Lett* 2012;**212**(2):106–12.

34.   Ahn S-H., Shah YM., Inoue J., Morimura K., Kim I., Yim S., et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. *Inflamm Bowel Dis* 2008;**14**(7):908–20.

35.   Chiang JYL. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. *Expert Opin Drug Metab Toxicol* 2009;**5**(2):137–47.

36.   Bijland S., Rensen PCN., Pieterman EJ., Maas ACE., van der Hoorn JW., van Erk MJ., et al. Perfluoroalkyl Sulfonates Cause Alkyl Chain Length–Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice. *Toxicol Sci* 2011;**123**(1):290–303.

37.   Behr A-C., Kwiatkowski A., Ståhlman M., Schmidt FF., Luckert C., Braeuning A., et al. Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. *Arch Toxicol* 2020:1673–86.

38.   Ejderhamn J., Strandvik B. Serum bile acids in relation to disease activity and intake of dietary fibers in juvenile ulcerative colitis. *Digestion* 1991;**50**(3–4):162–9.

39.   Gnewuch C., Liebisch G., Langmann T., Dieplinger B., Mueller T., Haltmayer M., et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. *World J Gastroenterol* 2009;**15**(25):3134–41.

40.   Münch A., Söderholm JD., Ost A., Carlsson AH., Magnusson K-E., Ström M.

Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. *Aliment Pharmacol Ther* 2011;**33**(8):954–60.

41.   Meihoff WE., Kern F. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. *J Clin Invest* 1968;**47**(2):261–7.

42.   Halfvarson J., Brislawn CJ., Lamendella R., Vázquez-Baeza Y., Walters WA., Bramer LM., et al. Dynamics of the human gut microbiome in inflammatory bowel disease. *Nat Microbiol* 2017;**2**:1–9.

43.   Lenicek M., Duricova D., Komarek V., Gabrysova B., Lukas M., Smerhovsky Z., et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. *Inflamm Bowel Dis* 2011;**17**(6):1322–7.

Figure Legends

Figure 1. Partial correlation network of clinical variables group (UC, CD and HC), age and sex, PFAS, primary BAs and secondary BAs. Edge colors: blue for negative correlations and red for the positive correlations, the strength of the line shows the strength of the correlation. Edge ranges adjusted between ± 0.22 to 0.75.

Figure 2. The effect of *ex vivo* exposure of PFOA on intestinal barrier function as measured by conductance, A) ileal and B) colonic conductance (G), macromolecular passage as assessed by FITC-dextran flux across C) ileal mucosa and D) colonic mucosa and stimulated secretory response to Charbachol, E) ileal and F) colonic short circuit current (Isc) after exposure to 10 µM and 100 µM PFOA and vehicle (DMSO). N=4-5. Data are presented as median with range (min/max), significance levels are calculated with Kurskal-Wallis and Mann-Whitney U-analysis, ($p<0.05$ [*], $p<0.01$ [**], non-significant [ns]).

Figure 3. Spearman correlations between PFAS and BAs in A) UC B) CD and C) HC. Significant correlations ($p<0.05$) marked with a star (*).

Figure 4. The distribution of individual BAs in UC, CD and HC and grouped as primary conjucated (PRIM., CONJ.), primary free (PRIM., FREE), secondary conjucated (SEC., CONJ.) and secondary free (SEC., FREE).

Table 1. Clinical characteristics of patients with Crohn's disease (CD) and ulcerative colitis (UC)

	CD n=20	UC n= 20
Sex (n, %)		
Males	13 (65%)	13 (65%)
Females	7 (35%)	7 (35%)
Age at diagnosis (median, IQR)	59 (56-61)	59 (56-61)
Age at sampling (median, IQR)	67 (63-73)	66 (63-74)
Location (CD) (n, %)		
Terminal ileum (L1)	11 (55%)	
Colon (L2)	5 (25%)	
Ileocolon (L3)	4 (20%)	
Disease extent (UC) (n, %)		
Left-sided		11 (55%)
Extensive		9 (45%)
Behaviour (n, %)		
Non-stricturing non-penetrating	8 (40%)	
Stricturing or penetrating	12 (60%)	
Surgery (n, %)	12 (60%)	1 (5%)
Smoking (n, %)		
Current	6 (31.5%)	3 (15%)
Previous	6 (31.5%)	10 (50%)
Never	7 (37%)	7 (35%)

IQR:Interquartile range.

Table 2. Comparisons of fold change ratio of serum perfluoroalkyl substances (PFAS) concentration in ulcerative colitis (UC), Crohn's disease (CD) and healthy controls (HC) with adjusted p-values. A negative fold change value represents a decrease in PFAS-levels. Significantly changing PFAS ($p<0.05$) are marked in bold.

	Fold change UC to HC	UC *vs* HC p-value	Fold change CD to HC	CD *vs* HC p-value	Fold change CD to UC	CD *vs* UC p-value
PFHpA	1.75	0.068	1.25	0.105	-1.40	0.262
PFHxS	1.33	0.108	1.26	0.790	-1.06	0.194
PFOA	2.10	**0.023**	1.45	0.858	-1.45	0.120
PFNA	1.17	0.115	-1.33	0.973	-1.56	**0.027**
PFOS	2.07	**0.026**	1.10	0.957	-1.88	**0.027**
PFDA	1.05	0.345	-1.85	0.634	-1.95	**0.005**
PFUnDA	-1.39	0.695	-1.95	0.641	-1.40	**0.030**
PFTrDA	-1.33	0.676	-1.33	0.215	1.00	0.083
ΣPFAS	2.04	**0.028**	1.21	0.437	-1.68	**0.032**

Table 3. Comparisons of fold change ratio of serum bile acids (BAs) concentration in ulcerative colitis (UC), Crohn's disease (CD) and healthy controls (HC) with adjusted *p*-values. A negative fold change value represents a decrease in BA levels. Significantly changing BA (*p*<0.05) are marked in bold.

BA	Type of BA	Fold change UC to HC	UC *vs* HC *p*-value	Fold change CD to HC	CD *vs* HC *p*-value	Fold change CD to UC	CD *vs* UC *p*-value
CA	primary (free)	-1.21	0.0839	1.25	0.4587	1.51	**0.0017**
CDCA	primary (free)	-1.10	**0.0100**	2.54	**0.0056**	2.78	**0.0001**
TCDCA	primary taurine-conjugated	-1.65	0.1844	-7.03	**0.0022**	-4.26	0.0804
GCA	primary glycine-conjugated	-1.88	0.0522	-2.90	**0.0133**	-1.54	**0.0482**
GHDCA	primary glycine-conjugated	-3.41	0.4722	-1.69	0.8270	2.02	0.1238
GCDCA	primary glycine-conjugated	-1.49	**0.0354**	-1.87	0.1380	-1.26	0.0443
Tα+βMCA	secondary taurine-conjugated	-2.05	**0.0010**	-9.85	**0.0519**	-4.80	0.2440
THCA	secondary taurine-conjugated	-7.62	0.4676	-160.00	**0.0022**	-21.00	0.1658
TDCA	secondary taurine-conjugated	-1.12	0.9974	-2.32	0.1070	-2.08	0.1123
TLCA	secondary taurine-conjugated	-1.09	0.0696	-3.43	**0.0082**	-3.14	**0.0225**
GHCA	secondary glycine-conjugated	-1.99	0.1279	-2.77	**0.0002**	-1.40	0.1297
GUDCA	secondary glycine-conjugated	-1.63	0.1768	-1.29	0.1653	1.26	0.0668
GDCA	secondary glycine-conjugated	-1.81	0.1511	-2.32	0.2764	-1.28	0.2759
GLCA	secondary glycine-conjugated	-3.10	**0.0238**	-2.61	**0.0293**	1.19	0.3195
UDCA	secondary	1.25	0.6504	2.89	**0.0047**	2.30	**0.0340**
HDCA	secondary	1.68	0.4317	4.10	**0.0016**	2.44	0.0088
12-oxoLCA	secondary	1.22	0.2645	-1.59	**0.0480**	-1.94	0.1143
DCA	secondary	-1.35	0.1143	1.43	0.5410	1.93	0.3599
LCA	secondary	1.45	0.7307	-1.25	0.8851	-1.81	0.5002
ΣPrimary BA		-1.67	**0.0173**	-2.05	0.0223	-1.23	**0.0001**
ΣSecondary BA		-1.35	0.5424	1.59	**0.0066**	2.14	0.0646
ΣTaurine conjugated BA		3.37	0.3658	-4.72	**0.0024**	-15.89	0.0945
ΣGlycine conjugated BA		-1.59	0.1192	-10.26	0.0886	-6.45	0.1227

Table 4. Differences in bile acid (BA) concentrations (ng/mL) in relation to Crohn's disease location, according to Montreal classification. Significantly changing BA ($p<0.05$) are marked in bold.

BA	Type of BA	Ileal involvement (L1, L3) n=15 median (min-max)	Colonic involvement (L2) n=5 median (min-max)	*p*-value
CA	primary (free)	76.05 (7.16 - 231.32)	15.42 (6.69 - 40.59)	**0.042**
CDCA	primary (free)	642.48 (31.18 - 1901.81)	48.68 (16.10 - 114.39)	**0.008**
TCDCA	primary taurine-conjugated	13.63 (0.90 - 103.87)	38.91 (12.76 - 131.47)	**0.042**
GCA	primary glycine-conjugated	81.67 (25.48 - 420.87)	109.95 (44.33 - 179.61)	1.000
GHDCA	primary glycine-conjugated	4.78 (0.05 - 18.38)	4.22 (2.06 - 16.8)	0.672
GCDCA	primary glycine-conjugated	354.1 (160.94 - 1393.31)	459.65 (74.90 - 780.92)	0.672
Tα+βMCA	secondary taurine-conjugated	0.001 (0.001 - 13.61)	2.05 (0.98 - 25.85)	**0.002**
THCA	secondary taurine-conjugated	0.01 (0.01 - 0.01)	0.76 (0.01 - 1.87)	0.053
TDCA	secondary taurine-conjugated	5.42 (0.01 - 34.91)	41.6 (11.52 - 74.44)	**0.011**
TLCA	secondary taurine-conjugated	0.71 (0.01 - 3.70)	3.05 (0.94 - 5.58)	**0.019**
GHCA	secondary glycine-conjugated	0.95 (0.30 - 3.90)	3.64 (2.21 - 5.79)	**0.019**
GUDCA	secondary glycine-conjugated	29.38 (2.56 - 257.38)	7.65 (3.40 - 38.72)	0.066
GDCA	secondary glycine-conjugated	125.66 (0.14 - 731.04)	136.06 (48.46 - 666.84)	0.445
GLCA	secondary glycine-conjugated	7.06 (0.10 - 95.05)	8.51 (2.49 - 34.72)	0.612
UDCA	secondary	127.7 (9.34 - 963.98)	11.01 (8.65 - 78.71)	**0.004**
HDCA	secondary	604.39 (115.37 - 1781.55)	66.57 (23.09 - 291.09)	**0.004**
12-oxoLCA	secondary	6.69 (0.01 - 138.72)	11.13 (0.01 - 23.57)	0.735
DCA	secondary	507.88 (0.01 - 2888.4)	98.44 (31.21 - 701.53)	0.735
LCA	secondary	11.04 (0.004 - 80.05)	0.004 (0.004 - 15.22)	0.445
ΣPrimary BA		1662.7 (343.46 - 3206.9)	714.93 (159.01 - 1169.74)	0.197
ΣSecondary BA		1491.19 (131.21 - 5078.7)	329.64 (232.45 - 1834.34)	0.119
ΣTaurine conjugated BA		29.72 (0.97 - 109.34)	115.8 (26.96 - 170.99)	**0.011**
ΣGlycine conjugated BA		630.09 (235.9 - 2390.45)	1116.8 (184.26 - 1295.45)	0.800

Figure 1

Figure 2.

Figure 3

Figure 4

UC   CD   HC

PRIM., CONJ.   PRIM., FREE   SEC., CONJ.   SEC., FREE

■ GCA ■ GCDCA ■ TCDCA ■ CA ■ CDCA ■ GDCA ■ GHCA ■ GHDCA ■ GLCA ■ GUDCA ■ Ta_bMCA ■ TDCA ■ TLCA ■ THCA ■ 12_oxoLCA ■ DCA ■ HCA ■ HDCA ■ LCA ■ UDCA